Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Differentiated cell

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    308 result(s) found for: Differentiated cell. Displaying page 1 of 16.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2004-000860-28 Sponsor Protocol Number: 02CLLIII Start Date*: 2004-12-02
    Sponsor Name:ribosepharm GmbH
    Full Title: PHASE III, OPEN-LABEL, RANDOMIZED, MULTICENTER EFFICACY AND SAFETY STUDY OF BENDAMUSTINE HYDROCHLORIDE VERSUS CHLORAMBUCIL IN TREATMENT-NAÏVE PATIENTS WITH (BINET STAGE B/C) B-CLL REQUIRING THERAPY
    Medical condition: Hematopoietic insufficiency with non-hemolysis-induced Hb <10 g/dL Thrombocytopenia <100x109/L (equivalent to Binet stage C) B symptoms Rapidly progressive disease (such as rapid lymphoma growth, r...
    Disease: Version SOC Term Classification Code Term Level
    7 10008956 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000327-18 Sponsor Protocol Number: CLL 2007 FMP Start Date*: 2007-07-06
    Sponsor Name:GOELAMS
    Full Title: Phase III, multicenter, European, randomized trial comparing the combination Fludarabine-Cyclophosphamide-Rituximab (FCR) with the combination Fludarabine-Cyclophosphamide-Campath (FCCam) in previo...
    Medical condition: Rituximab and Campath are two antibodies directed against CD20 and CD52 antigen, respectively. The highest response rate in the B-CLL treatment has been obtained by the association of Fludarabine,...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004937-26 Sponsor Protocol Number: GELLC-7 Start Date*: 2017-07-13
    Sponsor Name:Fundación PETHEMA
    Full Title: A multicenter, non-randomized, open label study to evaluate the efficacy and security of Ibrutinib followed by ofatumumab consolidation in previously untreated patients with Chronic Lymphocytic Leu...
    Medical condition: Chronic Lymphocytic Leukemia or Lymphocytic Small Cell Lymphoma without previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10051812 Small cell lymphocytic lymphoma LLT
    20.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003936-10 Sponsor Protocol Number: D8220C00027 Start Date*: 2022-06-28
    Sponsor Name:AstraZeneca AB
    Full Title: MAJIC: A Phase III Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia o...
    Medical condition: Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) ES (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003079-32 Sponsor Protocol Number: CC-5013-CLL-008 Start Date*: 2009-06-19
    Sponsor Name:Celgene Corporation
    Full Title: ESTUDIO FASE 3, MULTICÉNTRICO, ALEATORIZADO, ABIERTO Y DE GRUPOS PARALELOS PARA VALORAR LA EFICACIA Y SEGURIDAD DE LENALIDOMIDA (REVLIMID®) FRENTE A CLORAMBUCILO COMO TERAPIA DE PRIMERA LÍNEA EN PA...
    Medical condition: TERAPIA DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON LEUCEMIA LINFOCÍTICA CRÓNICA DE CÉLULAS B NO TRATADOS PREVIAMENTE (FIRST-LINE THERAPY FOR PREVIOUSLY UNTREATED ELDERLY PATIENTS WITH B-CELL CHRON...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) HU (Completed) IT (Completed) FR (Completed) NL (Completed) DK (Completed) SK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-002987-24 Sponsor Protocol Number: 152CL201 Start Date*: 2007-06-25
    Sponsor Name:Biogen Idec Ltd
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclopho...
    Medical condition: Relapsed Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Prematurely Ended) ES (Completed) IT (Prematurely Ended) FR (Completed) DE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) SK (Completed) PT (Prematurely Ended) LT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003465-33 Sponsor Protocol Number: PLRG12 Start Date*: 2019-04-24
    Sponsor Name:Polish Lymphoma Research Group - PLRG
    Full Title: Acalabrutinib in CLL and MCL patients subjected to allogeneic hematopoietic stem cell transplantation (alloSCT).
    Medical condition: Mantle Cell Lymmphoma (MCL) Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012807-25 Sponsor Protocol Number: IIL-MCL0208 Start Date*: 2010-01-28
    Sponsor Name:IIL INTERGRUPPO ITALIANO LINFOMI ONLUS
    Full Title: A PHASE III MULTICENTER, RANDOMIZED STUDY WITH LENALIDOMIDE (Revlimid) MAINTENANCE VERSUS OBSERVATION AFTER INTENSIFIED INDUCTION REGIMEN CONTAINING RITUXIMAB FOLLOWED BY HIGH DOSE CHEMOTHERAPY A...
    Medical condition: Mantel cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    9.1 10061275 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017449-72 Sponsor Protocol Number: 1840 Start Date*: 2010-01-14
    Sponsor Name:FRED HUTCHINSON CANCER RESEARCH CENTER UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE SEATTLE CHILDREN
    Full Title: Nonmyeloablative Conditioning with Pre- and Post-Transplant Rituximab followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients with Advanced Chronic Lymphocytic Leukem...
    Medical condition: Patients with Advanced Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-000286-23 Sponsor Protocol Number: MS200662_0001 Start Date*: 2016-04-27
    Sponsor Name:Telios Pharma, Inc.
    Full Title: Phase I/II, First in Human, Dose Escalation Trial of TL-895 in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansion in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia ...
    Medical condition: B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003900 B-cell lymphomas NEC HLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003908 B-cell small lymphocytic lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001015-28 Sponsor Protocol Number: LLC 2007 SA Start Date*: 2007-07-27
    Sponsor Name:CHU TOURS
    Full Title: Single-agent rituximab as maintenance treatment versus observation after combined induction immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than 65 years...
    Medical condition: The trial compares single-agent rituximab as maintenance treatment versus observation after combined immunochematherapy with fludarabine, cyclophosphamide and rituximab (FCR) in patients older than...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009310 CLL LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011225-14 Sponsor Protocol Number: Le.P.Re. Study Start Date*: 2009-05-22
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A PROSPECTIVE, MULTICENTER PHASE II STUDY EVALUATING PREDICTIVE FACTORS FOR LENALIDOMIDE TREATMENT RESPONSE IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS.
    Medical condition: Must have a documented diagnosis of B-cell CLL (IWCLL guidelines for the diagnosis and treatment of chronic lymphocytic leukemia, [Hallek M et al, 2008]).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008956 Chronic lymphatic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000243-10 Sponsor Protocol Number: Hx-CD20-407 Start Date*: 2007-05-16
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with fludarabine and cyclophosphamide, in patients with previ...
    Medical condition: B-cell Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) CZ (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-007434-20 Sponsor Protocol Number: RV0272 Start Date*: 2008-03-19
    Sponsor Name:Deptartment of Hematology, Karolinska University Hospital
    Full Title: Phase I (II) study of the combination of lenalidomide and alemtuzumab in patients with chemotherapy refractory chronic lymphocytic leukemia (CLL)
    Medical condition: Refractory or relapsed chronic lymphocytic leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001824-30 Sponsor Protocol Number: BEN-CAM Start Date*: 2008-06-17
    Sponsor Name:Associazione Malattie Sangue Onlus
    Full Title: Phase II study of the combination Bendamustine and sc Alemtuzumab for patients with refractory or relapsed B-cell chronic lynphocytic leukemia
    Medical condition: patients whit LLC
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008958 Chronic lymphocytic leukaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003012-35 Sponsor Protocol Number: HM07/8281 Start Date*: 2012-06-12
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: CLARET: CLL Levels following Alemtuzumab in Responders to Early Therapy: A randomised, phase III trial to assess alemtuzumab consolidation therapy in patients with chronic lymphocytic leukaemia (CL...
    Medical condition: Chronic lymphocytic leukaemia (CLL).
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000722-96 Sponsor Protocol Number: PS-CLL-005 Start Date*: 2022-02-09
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: Lymph Node Microenvironment Modifications in Patients with CLL Treated with Venetoclax-based regimens
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002476-15 Sponsor Protocol Number: GIMEMALLC0405 Start Date*: 2005-07-28
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: Phase II pilot trial to evaluate the efficacy and safety of a first-line combined therapeutic approach for young (> = 60 years old) CLL patients with advanced and progressive disease stratif...
    Medical condition: CLL patients (diagnosis of CLL according to NCI criteria) with the following characteristics: Advanced stage or progressive disease with at least 2 clinical features of activity. Previously untreat...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005049-36 Sponsor Protocol Number: CAMPATH Start Date*: 2005-02-03
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
    Full Title: CAMPATH-1H MONOCLONAL ANTIBODY AS MANTEINANCE THERAPY AFTER FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINATION REGIMEN AS 2ND LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
    Medical condition: B-CLL DISEASE
    Disease: Version SOC Term Classification Code Term Level
    Nd 10008958 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006694-24 Sponsor Protocol Number: IV-A05-LL-01-PR.03 Start Date*: 2007-07-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia
    Medical condition: relapsed or refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 12:13:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA